Two large randomized controlled trials investigating the cardiovascular safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors—empagliflozin and canagliflozin—have shown a significant reduction in hospitalizations because of heart failure with both drugs [35, 36]. The gene discussed is SLC5A2; the disease is heart failure.